Ozone treatment associated with lymphatic drainage for cellulite treatment

The requested reference [d154890cd9bf906856d548ffd472a5fbb6559730] no longer exists in our database. It has been replaced by the current reference: [389e7887e47a2fd0ff215abe09cc2195b198ca4b]

Authors
Category Primary study
Registry of TrialsBrazilian Registry of Clinical Trials
Year 2021
INTERVENTION: D063926 Experimental group: 20 women who have cellulite in the buttocks and hamstring region will receive subcutaneous injections of ozone at a concentration of 10 micrograms/ml with injected volume at each point of 2 ml at a distance of 5 cm between each point in the region to be treated and after finishing with manual lymphatic drainage. Control group: 20 women with cellulite in the buttocks and hamstring region will receive 2 ml saline injections at the site (in the entire region to be treated) and then massage in the same way as the experimental group. CONDITION: Cellulite,edema D004487 D063926 PRIMARY OUTCOME: The primary outcome is a reduction in cellulite by at least 50% compared to placebo, which will be determined by evaluating the photographic and thermographic record before and after the intervention.; To assess the improvement or reduction of cellulite, the Fibro Edema Geloid Severity Scale will be used and photographic and thermographic records of the treated area will be performed. This evaluation will be done at the beginning and at the end of the treatment. The images will be evaluated by two independent operators, without one having access to the other's evaluation. SECONDARY OUTCOME: The secondary outcome is improved patient satisfaction, which will be determined through validated questionnaires. ; Participants will answer the adapted questionnaires: Patient Satisfaction Analysis, Segot‐chicq et al. (2007) and the Global Aesthetic Improvement Scale (GAIS), Narins (2003), which is used to classify the response to treatments, allowing a comparative assessment at different times after the therapeutic intervention. INCLUSION CRITERIA: The sample will be composed of patients of both genders aged between 18 and 70 years who present gynoid lipodystrophy and who consent to sign and date the consent form and are available to follow the protocol
Epistemonikos ID: 5feba9c21a23e1ea6e44e07975e2f5474f286cb7
First added on: Aug 25, 2024